Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;83(4):909-922.
doi: 10.1111/bcp.13161. Epub 2016 Dec 4.

Sertraline Use in the First Trimester and Risk of Congenital Anomalies: A Systemic Review and Meta-Analysis of Cohort Studies

Affiliations
Free PMC article
Review

Sertraline Use in the First Trimester and Risk of Congenital Anomalies: A Systemic Review and Meta-Analysis of Cohort Studies

Zi-Qi Shen et al. Br J Clin Pharmacol. .
Free PMC article

Abstract

Aim: To perform a meta-analysis of available cohort studies on the association between sertraline use by pregnant women in the first trimester and the findings of congenital anomalies in infants.

Methods: A comprehensive search of articles published from the index date up to 31st December 2015 investigating the aforementioned associations was conducted on PubMed and Web of Science. Mesh headings used included the terms "serotonin reuptake inhibitor," "sertraline," "congenital anomalies" and "obstetrical outcome."

Results: Twelve cohort studies that involved 6 468 241 pregnant women were identified. We summarized odds ratios (ORs) and 95% confidence intervals (CIs) of congenital anomalies using the random-effects model. Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8). Additionally, positive but nonsignificant associations between sertraline use and congenital anomalies of the nervous system (OR = 1.39; 95% CI = 0.83-2.32; I2 = 0%; n = 5), digestive system (OR = 1.23; 95% CI = 0.76-1.98; I2 = 0%; n = 5), eye, ear, face and neck (OR = 1.08; 95% CI = 0.33-3.55; I2 = 32.1%; n = 3), urogenital system (OR = 1.03; 95% CI = 0.73-1.46; I2 = 0%; n = 5), and musculoskeletal system (OR = 0.97; 95% CI = 0.69-1.36; I2 = 0%; n = 5) were observed.

Conclusion: This meta-analysis suggested that the use of sertraline use by pregnant women in the first trimester had an increased risk of cardiovascular-related malformations as well as atrial and/or ventricular septal defects in infants. Meanwhile, nonsignificant associations between sertraline use and other congenital anomalies were found. More cohort studies are warranted to provide detailed results of other congenital anomalies.

Keywords: antidepressive agents; cohort studies; congenital anomalies; meta-analysis; pregnancy; sertraline.

Figures

Figure 1
Figure 1
Flow‐chart of study selection
Figure 2
Figure 2
Forest plots of the relationship between sertraline use and risk of cardiovascular‐related malformations. Squares indicate study‐specific risk estimates (size of the square reflects the study‐specific statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamond indicates the summary odds ratio with its 95% CI. OR: odds ratio
Figure 3
Figure 3
Forest plots of the relationship between sertraline use and congenital anomalies of the nervous system, digestive system, eye, ear, face and neck, urogenital system, and musculoskeletal system. Squares indicate study‐specific risk estimates (size of the square reflects the study‐specific statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamond indicates the summary odds ratio with its 95% CI

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles
Feedback